Commentary published following an interview with two of the lead authors on the RNA workstream charter publication. RNA technologies, including mRNA therapeutics, have emerged as a promising drug modality because of their essential role in protein expression and their potential versatility in manufacturing. As a result, RNA is in the global spotlight and is an industry priority because of its use to combat COVID-19.
This conversation with the authors highlights the important challenges within the RNA field that are being addressed by the RNA workstream within BioPhorum Cell & Gene Therapy . The paper introduces this critical area and shows its unique challenges, not only those around mRNA therapeutics but how these challenges could negatively impact companies and the RNA industry. The team identified more than 50 challenges grouped into a final list of 15 distinct topics – each of them will be worked on separately by dedicated sub-teams.